Welcome to our dedicated page for Helius Med Technologies SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage device makers like Helius Medical Technologies often bury pivotal updates—FDA feedback on PoNS, reimbursement milestones, cash-runway details—inside dense exhibits. Missing a single line about a new multiple-sclerosis study could upend your valuation. Stock Titan’s AI surfaces those details instantly, turning every line of the Helius Medical Technologies annual report 10-K simplified into clear, actionable data.
Need Helius Medical Technologies SEC filings explained simply? You’ll receive real-time alerts the moment a Helius Medical Technologies quarterly earnings report 10-Q filing or Helius Medical Technologies 8-K material events explained hits EDGAR. Understanding Helius Medical Technologies SEC documents with AI feels intuitive, not technical—section-by-section summaries spotlight device revenue, clinical-trial costs, and capital raises.
- Insider moves: Track Helius Medical Technologies Form 4 insider transactions real-time and pinpoint buying or selling before the market reacts.
- Executive pay: Drill into each Helius Medical Technologies proxy statement executive compensation without scrolling past pages of tables.
- Event catalysts: Rapidly assess 8-K disclosures on clinical results, supply agreements, or VA purchasing contracts.
From Helius Medical Technologies earnings report filing analysis to monitoring Helius Medical Technologies insider trading Form 4 transactions, coverage spans every form. Need a quick read on Helius Medical Technologies executive stock transactions Form 4? It’s already on your dashboard, complete with AI-powered commentary. Compare quarter-over-quarter PoNS unit sales, watch cash levels, and gauge regulatory momentum in minutes—all with Stock Titan’s real-time, AI-driven insight engine.
Helius Medical Technologies, Inc. is soliciting proxies for a virtual special meeting to consider five proposals including the election of one director, Nasdaq approvals for issuance of shares on exercise of warrants tied to strategic advisors Pantera Capital and Summer Wisdom and warrants tied to acceptance of Solana (SOL) cryptocurrency, and an amendment to increase available shares under the 2022 Equity Incentive Plan by 4,000,000 shares. The Board unanimously recommends voting FOR the director nominee and Proposals 2–4. The record date is September 26, 2025 and there were 40,299,220 shares outstanding on that date. The filing discloses executive compensation policies, 2024 base salaries and bonus outcomes (Bonuses paid at 83% of target), significant equity grants in 2024 (e.g., options of 808,000 shares to the CEO), and September 24, 2025 side letters providing one-time cash bonuses of $890,000 and $610,000 to the CEO and CFO respectively, offsetting other potential post-transaction payments. The document details committee structure, independence determinations, and insider trading and clawback policies.
Solana Rocket Holdings Limited and CHUNG Wai Shing jointly disclosed beneficial ownership in Helius Medical Technologies (HSDT). They report shared voting and dispositive power over 4,040,871 Class A shares, representing 9.99% of the outstanding shares based on 40,295,612 shares outstanding as of September 24, 2025. Solana Rocket directly holds 3,887,319 shares plus pre-funded warrants for up to 10,936,107 shares and cash stapled warrants for up to 14,823,426 shares. A Beneficial Ownership Blocker limits exercise of the warrants so the reporting persons are capped at 9.99% (calculated to include 153,552 shares issuable under partial exercise). The filing includes a joint filing agreement as Exhibit 99.1.
Fusion Summer Limited and CHEE Choon Wee disclosed a joint Schedule 13D reporting the acquisition of 6,830,402 shares of Helius Medical Technologies Class A common stock, representing 17.0% of the outstanding shares based on 40,295,612 shares. Fusion Summer paid approximately $47.0 million in a private placement (PIPE) that closed on September 18, 2025. Mr. CHEE, the ultimate controller of Fusion Summer, was appointed Executive Chairman effective at closing. The reporting persons hold shared voting and dispositive power over the shares and state the securities were acquired for investment purposes.
Chee Choon Wee filed a Form 3 reporting initial beneficial ownership in Helius Medical Technologies, Inc. (HSDT). The filing shows 6,830,402 shares of common stock held indirectly through Fusion Summer Limited, 6,830,402 stapled warrants exercisable from 09/18/2025 for 36 months at a $10.134 exercise price, and 1,109,118 restricted stock units granted 09/18/2025, each convertible into one share under the companys 2022 Equity Incentive Plan.
Helius Medical Technologies completed a $500 million PIPE on September 18, 2025 and launched a Solana-centric digital asset treasury strategy to acquire SOL via open-market purchases and build Solana treasury operations. The PIPE included cash and cryptocurrency purchasers buying combinations of common shares, pre-funded warrants and stapled warrants; exercise of the cryptocurrency-related warrants is conditioned on stockholder approval. The company’s PoNS® portable neuromodulation device is cleared in the U.S. for short-term treatment of gait deficit due to mild-to-moderate MS, authorized in Canada for three indications and is Class IIa in Australia. Common stock trades on Nasdaq under HSDT (last reported price $23.17 on September 18, 2025) and there were 39,382,328 shares outstanding as of September 18, 2025.
FAQ
What is the current stock price of Helius Med Technologies (HSDT)?
What is the market cap of Helius Med Technologies (HSDT)?
